MarketPulse
FDA approvalclinical trialpublic offering

Candel Therapeutics Raises $100M via Public Share Offering

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Candel Therapeutics raises $100M via public share offering to fund commercialization of its prostate cancer gene therapy and ongoing lung cancer clinical trials.

Candel Therapeutics Raises $100M via Public Share Offering
$CADLpositive

Candel Therapeutics priced a public offering of 18.3 million shares at $5.45 per share, generating $100 million in gross proceeds. The offering is expected to close on February 23, 2026.

The biopharmaceutical company intends to allocate the capital toward launch readiness and commercialization efforts for aglatimagene besadenovec, its gene therapy candidate for localized prostate cancer. The funds will also support ongoing phase 3 clinical trials for the same treatment in non-small cell lung cancer indications.

Additionally, Candel plans to direct a portion of the proceeds toward general corporate purposes. The offering expands the company's financial resources as it advances its clinical pipeline and prepares commercial infrastructure for its lead candidate.

Topics

FDA approvalclinical trialpublic offeringbiopharmaceuticalprostate cancerimmunotherapyaglatimagene besadenovec

Source: GlobeNewswire Inc.

Back to newsPublished Feb 20

Related Coverage

GlobeNewswire Inc.

FDA Expands VYVGART Approval to All Generalized Myasthenia Gravis Patients

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.

ARGX
GlobeNewswire Inc.

Biofrontera to Report Q1 2026 Results as PDT Expansion Accelerates

Biofrontera to report Q1 2026 results May 14, advancing Ameluz® commercialization and clinical expansion into skin cancers and acne.

BFRIBFRIW
GlobeNewswire Inc.

Arcutis Bolsters Team With $269K RSU Grants as FDA Expands ZORYVE Potential

Arcutis granted 309,000 equity awards to 40 new hires. Company seeks FDA approval to expand ZORYVE cream to treat atopic dermatitis in infants as young as 3 months.

ARQT
GlobeNewswire Inc.

Alpha Tau Completes Pivotal Study for Skin Cancer Treatment, Targeting FDA Approval

Alpha Tau Medical completes enrollment of 88 patients in pivotal skin cancer trial, advancing toward FDA approval of Alpha DaRT® for recurrent squamous cell carcinoma.

DRTSDRTSW
Investing.com

Moderna Surges on Hantavirus Vaccine Success, Signaling mRNA Platform Diversification

Moderna stock rises after positive Phase 1 hantavirus vaccine data, with analysts raising price targets amid signs of mRNA platform diversification beyond COVID.

MRNA
GlobeNewswire Inc.

Pharvaris Raises $115M to Advance Rare Disease Pipeline

Pharvaris raises $115M through 3.87M share offering at $29.68 per share to advance oral angioedema treatments; Phase 3 data expected Q3 2026.

PHVS